MA47676A - Polythérapie - Google Patents

Polythérapie

Info

Publication number
MA47676A
MA47676A MA047676A MA47676A MA47676A MA 47676 A MA47676 A MA 47676A MA 047676 A MA047676 A MA 047676A MA 47676 A MA47676 A MA 47676A MA 47676 A MA47676 A MA 47676A
Authority
MA
Morocco
Prior art keywords
polytherapy
Prior art date
Application number
MA047676A
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Arilla Maria Cristina Villellas
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA47676A publication Critical patent/MA47676A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA047676A 2017-03-01 2018-02-28 Polythérapie MA47676A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17158607 2017-03-01

Publications (1)

Publication Number Publication Date
MA47676A true MA47676A (fr) 2021-06-02

Family

ID=58192228

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047676A MA47676A (fr) 2017-03-01 2018-02-28 Polythérapie

Country Status (10)

Country Link
US (3) US11224596B2 (fr)
EP (2) EP3589323B1 (fr)
JP (2) JP7307682B2 (fr)
KR (2) KR20190121315A (fr)
CN (1) CN110831630A (fr)
BR (1) BR112019017901A2 (fr)
EA (1) EA201991997A1 (fr)
MA (1) MA47676A (fr)
PH (1) PH12019502002A1 (fr)
WO (1) WO2018158280A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
WO2017049321A1 (fr) 2015-09-17 2017-03-23 Miller Marvin J Composés hétérocycliques contenant de la benzylamine et compositions utiles contre une infection mycobactérienne
EP3472158A1 (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Composés hétérocycliques en tant qu'agents antibacteriens
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
EP3589323B1 (fr) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Polythérapie pour le traitement de la tuberculose
EP3976031A4 (fr) * 2019-05-28 2023-07-12 Shionogi & Co., Ltd Médicament destiné au traitement d'une infection mycobactérienne caractérisé par la combinaison d'un inhibiteur bc1 avec de la clarithromycine ou de l'azithromycine et de la clofazimine
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
AU2020404130B2 (en) * 2019-12-20 2025-10-02 Qurient Co., Ltd. A pharmaceutical oral dosage form of Q203
EP4164645A4 (fr) * 2020-06-15 2024-07-10 The Global Alliance for TB Drug Development, Inc. Composition antibactérienne combinée et procédé de thérapie antibactérienne
CN112089713B (zh) * 2020-09-18 2022-02-22 中国科学院广州生物医药与健康研究院 一种基于吡唑并[1,5-a]吡啶类化合物的治疗结核分枝杆菌感染的药物组合物
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
CN115531388B (zh) * 2022-11-04 2024-03-22 首都医科大学附属北京胸科医院 治疗结核病的药物组合物
CN121604963A (zh) 2023-07-18 2026-03-03 詹森药业有限公司 包含贝达喹啉、普托马尼或德拉马尼的至少三种抗生素与细胞色素bc1抑制剂的组合产品及其在治疗分枝杆菌感染中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ295528A (en) 1994-11-15 1999-03-29 Upjohn Co Bicyclic oxazine and thiazine oxazolidinone antibacterials
ES2162047T3 (es) 1995-05-11 2001-12-16 Upjohn Co Oxazolidinonas con resto diazinilo y carbazinilo espirociclico y biciclico.
ES2343458T3 (es) 2002-07-25 2010-08-02 Janssen Pharmaceutica Nv Derivados de quinolina y su uso como inhibidores de micobacterias.
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
CA2672960A1 (fr) 2006-12-20 2008-07-10 Schering Corporation Nouveaux inhibiteurs de jnk
TW200901969A (en) 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
JP5613656B2 (ja) 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
EP2353008A2 (fr) 2008-09-22 2011-08-10 Oregon Health and Science University Méthodes permettant de détecter une infection par le bacille de koch
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
RU2608611C2 (ru) 2009-11-05 2017-01-23 Юниверсити Оф Нотр Дам Дю Лак СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
AU2012302176A1 (en) 2011-09-01 2014-04-17 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
JP6134319B2 (ja) 2011-09-01 2017-05-24 ノバルティス アーゲー ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物
ES2620668T3 (es) 2012-03-02 2017-06-29 Genentech, Inc. Derivados de amidas y sulfonamidas amido espirocíclicas
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2014015167A2 (fr) 2012-07-18 2014-01-23 University Of Notre Dame Du Lac Composés anti-infectieux 5,5-hétéroaromatiques
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
CN105745208A (zh) 2013-08-02 2016-07-06 韩国巴斯德研究所 一种抗感染化合物
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
WO2015107482A1 (fr) 2014-01-17 2015-07-23 Piramal Enterprises Limited Association pharmaceutique pour traiter la tuberculose
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
WO2016073524A1 (fr) 2014-11-03 2016-05-12 The Regents Of The University Of California Multithérapies médicamenteuses pour le traitement de la tuberculose
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
CA3025727A1 (fr) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Composes heterocycliques utilises en tant qu'agents antibacteriens
EP3472158A1 (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Composés hétérocycliques en tant qu'agents antibacteriens
EP3589323B1 (fr) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Polythérapie pour le traitement de la tuberculose

Also Published As

Publication number Publication date
EP3589323A1 (fr) 2020-01-08
PH12019502002A1 (en) 2020-06-29
KR20240053077A (ko) 2024-04-23
WO2018158280A1 (fr) 2018-09-07
EA201991997A1 (ru) 2020-01-22
EP3589323B1 (fr) 2024-04-03
KR20190121315A (ko) 2019-10-25
JP2020509040A (ja) 2020-03-26
US20240325387A1 (en) 2024-10-03
US11224596B2 (en) 2022-01-18
JP7307682B2 (ja) 2023-07-12
JP2023061973A (ja) 2023-05-02
EP4417262A2 (fr) 2024-08-21
US11918575B2 (en) 2024-03-05
EP4417262A3 (fr) 2024-11-27
US20200016154A1 (en) 2020-01-16
BR112019017901A2 (pt) 2020-05-12
US20220088012A1 (en) 2022-03-24
CN110831630A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3651772A4 (fr) Polythérapie anticancéreuse
EP3589248A4 (fr) Cryothérapies
MA47676A (fr) Polythérapie
DE202018003363U8 (de) Handgelenkssphygmomanometer
MA52090A (fr) Polythérapie
EP3634404C0 (fr) Inhibiteurs de magl à base de pyrazole
EP3697802A4 (fr) Analogues de saponine triterpénique
EP3515414A4 (fr) Polythérapie
EP3654852A4 (fr) Garrot
EP3634397A4 (fr) Chromophores ir à base de polyméthine hétérocyclyle
DK3568655T3 (da) Rekuperator
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
EP3721165C0 (fr) Charge militaire
EP3668507A4 (fr) Polythérapie
MA51576A (fr) Polythérapie
EP3609520A4 (fr) Polythérapie ciblée
EP3669219C0 (fr) Réseau echelle
EP3714787A4 (fr) Biocapteur
EP3728590C0 (fr) Nouvelles thiophosphoramidites
EP3675891A4 (fr) Polythérapie anticancéreuse
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
EP3689701A4 (fr) Boggie
EP3687383C0 (fr) Electrogustometre